GRAIL, Inc. — Investor Relations & Filings
Filings indexed
198
across all filing types
Latest filing
2026-04-28
Proxy Solicitation & In…
Country
US
United States of America
Listing
US
GRAL
GRAIL, Inc. is a healthcare company dedicated to detecting cancer early. Its mission is to reduce the global burden of cancer through early diagnosis when treatment may be more effective. The company's flagship product is the Galleri® test, a blood-based multi-cancer early detection (MCED) test. The Galleri test is designed to screen for a signal shared by multiple types of cancer, including many that lack recommended screening methods, often before symptoms appear. GRAIL develops its technology by leveraging next-generation sequencing (NGS), machine learning, and data from population-scale clinical studies. The company's focus is on identifying deadly cancers in their initial stages to improve patient outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEF 14A - GRAIL, Inc. (0001699031) (Filer) | 2026-04-28 | English | |
| SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject) | 2026-03-27 | English | |
| 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | |
| 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | |
| 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | |
| 8-K - GRAIL, INC. (0001699031) (Filer) | 2026-02-19 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 38160818 | DEF 14A - GRAIL, Inc. (0001699031) (Filer) | 2026-04-28 | English | ||
| 33060498 | SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject) | 2026-03-27 | English | ||
| 32896830 | 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | ||
| 32896829 | 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | ||
| 32896831 | 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | ||
| 32896832 | 8-K - GRAIL, INC. (0001699031) (Filer) | 2026-02-19 | English | ||
| 31355626 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31355656 | SCHEDULE 13G/A Filing | 2026-02-11 | English | ||
| 31355567 | SCHEDULE 13G/A Filing | 2026-02-09 | English | ||
| 13013383 | FORM 4 | 2026-01-16 | English | ||
| 13013385 | FORM 4 | 2026-01-16 | English | ||
| 13013386 | FORM 4 | 2026-01-16 | English | ||
| 13013388 | 8-K | 2026-01-12 | English | ||
|
2025
2 filings
| |||||
| 13013387 | FORM 4 | 2025-12-05 | English | ||
| 13013390 | FORM 4 | 2025-12-05 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
OncoTherapy Science, Inc.
Biopharmaceutical company researching and developing novel …
|
4564 | JP | Professional, scientific and te… |
|
Optipharm.CO.,LTD
Develops animal health solutions, biotherapeutics, and xeno…
|
153710 | KR | Professional, scientific and te… |
|
ORAGENICS INC
Biotechnology company developing intranasal therapeutics fo…
|
OGEN | US | Professional, scientific and te… |
|
ORGANOIDSCIENCES LTD.
Develops organoid-based technologies for drug development a…
|
476040 | KR | Professional, scientific and te… |
|
Orum Therapeutics, Inc.
Clinical-stage biotech developing degrader-antibody conjuga…
|
475830 | KR | Professional, scientific and te… |
|
OSR Holdings, Inc.
A healthcare holding company acquiring and developing innov…
|
OSRH | US | Professional, scientific and te… |
|
OS Therapies Inc
Clinical-stage immunotherapy company developing treatments …
|
OSTX | US | Professional, scientific and te… |
|
Ovation Science Inc.
Develops and licenses patented Invisicare® technology for e…
|
OVAT | CA | Professional, scientific and te… |
|
OXFORD BIODYNAMICS PLC
Develops and commercializes precision medicine tests for on…
|
OBD | GB | Professional, scientific and te… |
|
Oxurion NV
Acquires majority stakes in European pharmaceutical subcont…
|
OXUR | BE | Professional, scientific and te… |
GRAIL, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31638/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31638 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31638 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31638 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31638}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GRAIL, Inc. (id: 31638)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.